Australia is facing a rising number of prostate cancer cases, making early detection more critical for improving patient outcomes. Against this background, the market for PET imaging agents in the country is projected to grow at a 2% compound annual growth rate (CAGR) through 2033, according to GlobalData, a leading data and analytics company.

GlobalData’s report, “Nuclear Imaging Equipment Market Size by Segments, Share, Regulatory, Reimbursement, Installed Base and Forecast to 2036”, reveals that Australia’s PET imaging agents market accounted for around 10% of the Asia-Pacific (APAC) market in 2024. This growth is driven by the growing demand for next-generation imaging solutions and increasing healthcare investments across the region.

Telix Pharmaceuticals, an Australian cancer diagnostics company, is revolutionizing prostate cancer detection with its advanced imaging agent, Illuccix (gallium-68 (68Ga) gozetotide injection kit). This product has also garnered international recognition and recently received approval in Brazil. Developed for positron emission tomography (PET), this targets prostate-specific membrane antigen (PSMA) positive lesions, enabling precise detection of both localized and advanced prostate cancer.

Nidhi Bharti, Medical Devices Analyst at GlobalData, comments: “PSMA-targeted PET imaging represents a significant advancement in the detection of prostate cancer, particularly in its early stages or when PSA levels are low. The heightened sensitivity of PSMA PET imaging enables the identification of even small lesions that conventional methods may overlook, thus contributing to earlier detection and more precise staging.”

Utilizing a radiolabeled compound that selectively targets PSMA, this imaging technique facilitates the precise visualization of primary and metastatic cancer cells. Additionally, its high accuracy reduces unnecessary tests and extended hospital stays, offering a more efficient approach to prostate cancer management.

Bharti concludes: “PSMA-PET imaging is becoming a key tool in prostate cancer care. This technology allows clinicians to identify even the smallest lesions, providing crucial information that can directly influence treatment decisions, offering hope for more effective, individualized care, and ultimately improving patient survival rates.”